Review



non-contact microarray  (Gesellschaft fur Silizium-Mikrosysteme)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Gesellschaft fur Silizium-Mikrosysteme non-contact microarray
    Non Contact Microarray, supplied by Gesellschaft fur Silizium-Mikrosysteme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non-contact+microarray/non+contact+microarray/pm37914005-83-28-38
    Average 90 stars, based on 1 article reviews
    non-contact microarray - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Direct competitive assay for HER2 detection in human plasma using Bloch surface wave-based biosensors.
    Article Snippet: This was achieved by nanoplotting a 100 μg/mL solution of HER2 in PBS 1 × onto five separate regions along the sensing area of the 1D-PC using a non-contact microarray printer with a high precision printing system by GeSiM (25 μm accuracy, 650 pL per drop) (Fig. 1c(iv)).



    Similar Products

    non contact inkjet microarray printer  (SCIENION)
    95
    SCIENION non contact inkjet microarray printer
    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is <t>inkjet</t> printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.
    Non Contact Inkjet Microarray Printer, supplied by SCIENION, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non-contact+microarray/sciFLEXARRAYER+S12/pmc13380757-243-19-23
    Average 95 stars, based on 1 article reviews
    non contact inkjet microarray printer - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    non contact microarray spotter  (SCIENION)
    96
    SCIENION non contact microarray spotter
    Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen <t>microarray</t> technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).
    Non Contact Microarray Spotter, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non-contact+microarray/sciFLEXARRAYER+S3/pmc13388467-92-19-24
    Average 96 stars, based on 1 article reviews
    non contact microarray spotter - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    sciflexarrayer s3 non contact microarray  (SCIENION)
    96
    SCIENION sciflexarrayer s3 non contact microarray
    Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen <t>microarray</t> technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).
    Sciflexarrayer S3 Non Contact Microarray, supplied by SCIENION, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non-contact+microarray/sciFLEXARRAYER+S3/pm41674152-206-25-24
    Average 96 stars, based on 1 article reviews
    sciflexarrayer s3 non contact microarray - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    non contact sciflexarrayer s12 microarray spotter  (SCIENION)
    95
    SCIENION non contact sciflexarrayer s12 microarray spotter
    Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen <t>microarray</t> technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).
    Non Contact Sciflexarrayer S12 Microarray Spotter, supplied by SCIENION, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non-contact+microarray/sciFLEXARRAYER+S12/pmc12532290__ja5c12690_si_001-588-37-42
    Average 95 stars, based on 1 article reviews
    non contact sciflexarrayer s12 microarray spotter - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is inkjet printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.

    Journal: iScience

    Article Title: A rapid point-of-care test for vancomycin monitoring at the clinical bedside

    doi: 10.1016/j.isci.2026.116064

    Figure Lengend Snippet: The VANC-D4 assay (A) Fabrication of the VANC-D4 assay. SI-ATRP is used to grow POEGMA-co-GMA brushes on glass slides. Following SI-ATRP, VANC-BSA is inkjet printed into the polymer brush to create stable spots and fluorescently labeled anti-VANC antibodies (termed dAb) are printed on trehalose pads to create labile spots. (B) Sequential steps of the VANC-D4 assay. The steps of the VANC-D4 are (i) dispensing a blood sample on the surface, (ii) dissolution of the trehalose pads to release the fluorescently labeled dAb into solution, (iii) diffusion of the labeled dAb in the sample volume, (iv) detection of fluorescence signal from the antibody bound to immobilized VANC-BSA. (C) Representative VANC-D4 assay response in the presence of (i) no drug, (ii) low drug, and (iii) high drug concentration. (D) VANC monitoring across its clinical range using VANC-spiked whole blood diluted 100-fold in running buffer, analyzed in triplicate. The clinical range for the test is 1–45 μg/mL. Intensity values are shown, with error bars that represent the standard error of the means for n = 3 separate runs. The LOD for the presented dose-response curve was calculated to be 0.8 μg/mL.

    Article Snippet: Following polymerization, D4 assays were fabricated using non-contact inkjet printing methods as described elsewhere., VANC-BSA was printed using a non-contact inkjet microarray printer (Scienion, sciFLEXARRAYER Type S12).

    Techniques: Polymer, Labeling, Dissolution, Diffusion-based Assay, Fluorescence, Concentration Assay

    Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen microarray technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).

    Journal: Frontiers in Immunology

    Article Title: Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration

    doi: 10.3389/fimmu.2026.1824524

    Figure Lengend Snippet: Overview of the experimental workflow for analyzing retinal antigen profiles captured by serum autoantibodies from patients with different stages of AMD. Antibodies isolated from AMD patient serum were captured on Protein G magnetic beads and incubated overnight with porcine retinal lysates. Unbound retinal antigens were washed away, and antibody-bound antigens were subsequently subjected to MS analysis. Selected differentially expressed retinal antigen targets identified by MS were further evaluated and validated in serum and tear samples from AMD patients using antigen microarray technology. The image was created using BioRender.com ( https://biorender.com/ , accessed on 14. June 2026).

    Article Snippet: Commercially obtained antigens ( ) were spotted in triplicates onto nitrocellulose-coated slides (Oncyte, Grace Bio Labs, USA) using a non-contact microarray spotter (sciFLEXARRAYER S3, Scienion, Germany).

    Techniques: Isolation, Magnetic Beads, Incubation, Microarray

    Selection and validation of candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B) Heatmap showing the relative abundance of selected candidate retinal antigens across AMD stages. Red indicates increased abundance and blue indicates decreased abundance. Candidate antigens selected for further validation are highlighted with red boxes. (C–H) Antigen microarray validation of serum and tear autoantibody reactivity against selected retinal antigens, including PSMD6, HSPA12A, PTGES3, ATP5A1, PFKM, and SDHB, in CTRL and AMD subgroups. Data are presented as mean ± SE. *p < 0.05.

    Journal: Frontiers in Immunology

    Article Title: Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration

    doi: 10.3389/fimmu.2026.1824524

    Figure Lengend Snippet: Selection and validation of candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B) Heatmap showing the relative abundance of selected candidate retinal antigens across AMD stages. Red indicates increased abundance and blue indicates decreased abundance. Candidate antigens selected for further validation are highlighted with red boxes. (C–H) Antigen microarray validation of serum and tear autoantibody reactivity against selected retinal antigens, including PSMD6, HSPA12A, PTGES3, ATP5A1, PFKM, and SDHB, in CTRL and AMD subgroups. Data are presented as mean ± SE. *p < 0.05.

    Article Snippet: Commercially obtained antigens ( ) were spotted in triplicates onto nitrocellulose-coated slides (Oncyte, Grace Bio Labs, USA) using a non-contact microarray spotter (sciFLEXARRAYER S3, Scienion, Germany).

    Techniques: Selection, Biomarker Discovery, Microarray

    Validation and overlap analysis of selected candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B–G) A subset of candidate retinal antigen targets identified by serum autoantibody-based proteomic profiling, including FTH1, SAG, VIM, PRMT5, SEC22B, and HIST2H2AA3, was selected for further validation by antigen microarray analysis in serum and tear samples from CTRL and AMD subgroups. Data are presented as mean ± SE, with whiskers indicating 1.96 × SE.*p < 0.05. (H) Venn diagram showing the overlap among serum proteomics-positive results, serum autoantibody microarray-positive results, and tear autoantibody microarray-positive results. The antigen microarray analysis was performed as a targeted validation of selected MS-derived retinal antigen targets. Candidate antigens supported by multiple datasets are highlighted in red.

    Journal: Frontiers in Immunology

    Article Title: Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration

    doi: 10.3389/fimmu.2026.1824524

    Figure Lengend Snippet: Validation and overlap analysis of selected candidate retinal antigens recognized by serum and tear autoantibodies in patients with different stages of AMD. (A) Venn diagram showing shared and stage-specific differentially enriched retinal antigens captured by serum autoantibodies across AMD subgroups. (B–G) A subset of candidate retinal antigen targets identified by serum autoantibody-based proteomic profiling, including FTH1, SAG, VIM, PRMT5, SEC22B, and HIST2H2AA3, was selected for further validation by antigen microarray analysis in serum and tear samples from CTRL and AMD subgroups. Data are presented as mean ± SE, with whiskers indicating 1.96 × SE.*p < 0.05. (H) Venn diagram showing the overlap among serum proteomics-positive results, serum autoantibody microarray-positive results, and tear autoantibody microarray-positive results. The antigen microarray analysis was performed as a targeted validation of selected MS-derived retinal antigen targets. Candidate antigens supported by multiple datasets are highlighted in red.

    Article Snippet: Commercially obtained antigens ( ) were spotted in triplicates onto nitrocellulose-coated slides (Oncyte, Grace Bio Labs, USA) using a non-contact microarray spotter (sciFLEXARRAYER S3, Scienion, Germany).

    Techniques: Biomarker Discovery, Microarray, Derivative Assay